FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
April 15, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...
Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
February 06, 2019 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it has resumed per protocol dosing of patients...
FibroGen Reports First Quarter 2018 Financial Results
May 09, 2018 16:02 ET
|
FibroGen, Inc
Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018Conference Call Today at 5:00 p.m. Eastern Time/2:00...
Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
February 26, 2018 07:00 ET
|
Summit Therapeutics plc
MRS-T2 Data Provide Evidence of Early Impact of Ezutromid on Downstream Muscle HealthData Build on Positive Biopsy Findings that Showed Significant Decrease in Muscle Damage OXFORD, United Kingdom,...
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
December 06, 2017 02:00 ET
|
Summit Therapeutics plc
LIESTAL, Switzerland, OXFORD, England and CAMBRIDGE, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Santhera Pharmaceuticals (SIX:SANN), Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), Catabasis...
Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular Dystrophy
September 25, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress
June 14, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, June 14, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
aTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular Dystrophy
April 24, 2017 07:30 ET
|
aTyr Pharma Inc.
- 63% of Patients Observed Increased Muscle Strength - - Resolaris Demonstrated a Generally Well-Tolerated Safety Profile in Younger Patient Population - SAN DIEGO, April 24, 2017 (GLOBE NEWSWIRE)...
Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress
March 29, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, March 29, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
FibroGen Reports Fiscal 2016 Financial Results
March 01, 2017 16:02 ET
|
FibroGen, Inc.
SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and...